- Home
- VIR
as 06-20-2025 4:00pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 844.9M | IPO Year: | 2019 |
| Target Price: | $32.86 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $14.45 | Next Earning Date: | 07-31-2025 |
| Revenue: | $20,861,000 | Revenue Growth: | -73.79% |
| Revenue Growth (this year): | -77.71% | Revenue Growth (next year): | -0.77% |
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Napolitano Janet | VIR | Director | May 30 '25 | Sell | $5.05 | 3,200 | $16,148.80 | 16,416 | |
| De Backer Marianne | VIR | Chief Executive Officer | Apr 3 '25 | Sell | $5.95 | 79,712 | $474,238.57 | 769,505 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Argus Research
11 days ago
VIR: What does Argus have to say about VIR?
Simply Wall St.
24 days ago
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch
Business Wire
24 days ago
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Business Wire
a month ago
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
Argus Research
a month ago
VIR: Rating decreased to a SELL
Business Wire
a month ago
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
Simply Wall St.
a month ago
Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint
Business Wire
a month ago
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Compare VIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.